ArticleJournal of endocrinological investigation2026
Thyroid-stimulating hormone exacerbates mitochondrial energy dysregulation and cardiac remodeling with involvement of the AMPK/PGC-1α pathway.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsSubclinical hypothyroidism (SCH) is linked to the progression of heart failure (HF); however, the underlying mechanisms remain unclear. This study aimed to investigate the role of thyroid-stimulating hormone (TSH) in the regulation of HF and myocardial energy metabolism.
methodsIn vitro, cardiomyocytes were treated with TSH to assess pathological stress markers and mitochondrial energy metabolism. In vivo, a SCH model was established in thyrocyte-specific TSHR knockout mice, with concurrent isoproterenol (ISO)-induced HF. Serum FT4 and TSH levels, cardiac function, and myocardial energy metabolism (ATP levels, mitochondrial ultrastructure, key metabolic enzymes) were evaluated. Cardiomyocyte-specific TSHR knockout mice were used to confirm findings, and the involvement of the AMPK/PGC-1α pathway was investigated in vitro.
resultsIn vitro, TSH treatment increased the expression of pathological stress markers in cardiomyocytes. It also induced alterations in energy substrates, decreased ATP levels, and reduced mitochondrial membrane potential. In vivo, compared to the ISO group, mice in the SCH + ISO group exhibited more severe cardiac structural damage and functional impairment, accompanied by aggravated energy metabolism remodeling and mitochondrial dysfunction-characterized by lower ATP content, exacerbated mitochondrial ultrastructural damage, increased glycolysis, and decreased aerobic glucose oxidation. Notably, cardiomyocyte-specific TSHR knockout mitigated cardiac damage and metabolic remodeling in HF mice induced by ISO. Further mechanistic studies suggest that the AMPK/PGC-1α signaling pathway is involved in the regulation of TSH-mediated mitochondrial energy metabolism and cardiac remodeling.
conclusionOur findings indicate that SCH exacerbates HF progression and further implicate TSH/TSHR signaling in the regulation of myocardial energy metabolism.
Indexed as
Identifiers
42909573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.